Page 4 - Acinetobacter News Today

Scientists with the Texas A&M College of Agriculture and Life Sciences were among those providing the biochemical tools needed to help save a man's life through a unique emergency intervention in 2016.

The COVID-19 pandemic pushed back years of progress made in combating antimicrobial resistance (AR) in the United States.

Hospital-acquired infections (HAIs) are often particularly difficult to treat because the pathogens have developed resistance to common antibiotics.

Treatment of severe infections caused by pathogenic bacteria relies on ‘last resort’ antibiotics, but rising resistance by ‘superbugs’ to most clinically approved drugs leaves patients exposed to possible fatalities.

The pathogen Acinetobacter baumannii can survive on hospital surfaces -; without water -; for months, an ability that has helped it become a leading cause of hospital-acquired infections.

When treating acute infections in patients, health care providers must be able to quickly and accurately identify the best antibiotics for fighting the infection.

Researchers investigated the rising antimicrobial resistance in the Eastern Mediterranean Region of the World Health Organization from 2017 to 2019.

A new study published on the bioRxiv* preprint server has evaluated bacterial susceptibility during SARS-CoV-2 infection.

A global drive - led by University of the West of Scotland (UWS) - to tackle a drug-resistant superbug has received additional funding.

Experts predict that without intervention, the problem of multidrug-resistant bacterial infections could be catastrophic by 2050, killing nearly 10 million people each year.